Signal
Oricell Therapeutics raises over $100 million ahead of IPO to develop CAR-T therapy for liver cancer
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-10 08:28 UTCUpdated 2026-04-10 15:22 UTC
rss
clinical_trialsbiotech_fundingdrug_development
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Oricell Therapeutics, a Chinese biotech company specializing in CAR-T therapies, has completed a significant funding round exceeding $100 million as it prepares for an initial public offering. The company is advancing a novel cell therapy aimed at solid tumors, particularly liver cancer, which currently lacks CAR-T treatment options. This financing milestone supports Oricell's clinical development efforts and positions it to potentially introduce a pioneering therapy for liver cancer patients.
Entities
Oricell TherapeuticsCAR-T therapy for liver cancer
Score total
1.01
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Oricell’s recent $100M+ financing is its last before an anticipated IPO.
- The company is progressing clinical testing of its CAR-T therapy for liver cancer.
- There is increasing interest in CAR-T therapies beyond blood cancers, targeting solid tumors.
Why it matters
- Oricell’s CAR-T therapy could become the first treatment of its kind for liver cancer.
- The successful funding round supports advancement of novel cell therapies targeting solid tumors.
- This development highlights growing biotech innovation and investment in China’s cell therapy sector.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Oricell Therapeutics has raised over $100 million in its final funding round before going public
- Oricell is developing a CAR-T cell therapy targeting solid tumors, including liver cancer
How sources frame it
- Fierce Biotech: neutral
All evidence
All evidence
Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
BioPharma Dive · biopharmadive.com · 2026-04-10 15:22 UTC
Oricell Therapeutics has now raised over $100 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public.
Fierce Biotech · fiercebiotech.com · 2026-04-10 08:28 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- biopharmadive.com (1)
- fiercebiotech.com (1)